Inventor · disambiguated record
Damian Brockschnieder
Also filed as: BROCKSCHNIEDER DAMIAN
11 granted patents·12 pending applications·9 citations·filing 2009–2025
81Inventor score
Files withBAYER AG9Bayer Pharma AG9BAYER SCHERING PHARMA AG1BOEHRINGER INGELHEIM INT1BROAD INST INC1
Top patents by PatentIndex Score
23 records- 0178US10150773B2N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2016·Granted Dec 11, 2018·3 cites·8 claims
- 0277US9605008B2Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereofBayer Pharma AG·Filed 2014·Granted Mar 28, 2017·3 cites·24 claims
- 0375US10722501B2Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-A]pyridine-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-C][1,2,4]triazol-3-ones, and use thereofBAYER AG·Filed 2017·Granted Jul 28, 2020·2 cites·19 claims
- 0471US2025236654A1C-type natriuretic peptide engrafted antibodiesBAYER AG·Filed 2024·Application pending·0 cites
- 0565US9688699B23-(pyrimidine-2-yl)imidazo[1,2-a]pyridinesBayer Pharma AG·Filed 2015·Granted Jun 27, 2017·1 cites·11 claims
- 0661US2025361282A1Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2025·Application pending·0 cites
- 0759US12331094B2Atrial natriuretic peptide engrafted antibodiesBAYER AG·Filed 2019·Granted Jun 17, 2025·0 cites·18 claims
- 0856US2021079056A1C-type natriuretic peptide engrafted antibodiesBAYER AG·Filed 2019·Application pending·0 cites
- 0947US12390508B2Brain natriuretic peptide engrafted antibodiesBOEHRINGER INGELHEIM INT·Filed 2019·Granted Aug 19, 2025·0 cites·17 claims
- 1047US2011250135A1Piperazine Derivatives for Binding and Imaging Amyloid Plaques and Their UseBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 1146US2011243846A1Benzothiazole amides for detection of amyloid betaHASSFELD JORMA·Filed 2009·Application pending·0 cites
- 1245US12398120B2Substituted hydantoinamides as ADAMTS7 antagonistsBAYER AG·Filed 2020·Granted Aug 26, 2025·0 cites·17 claims
- 1345US2023027985A1Substituted hydantoinamides as adamts7 antagonistsBAYER AG·Filed 2020·Application pending·0 cites
- 1443US2022412975A1Characterizing modulators of adamts-7 and adamts-12BROAD INST INC·Filed 2020·Application pending·0 cites
- 1542US10214526B2Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereofBayer Pharma AG·Filed 2016·Granted Feb 26, 2019·0 cites·18 claims
- 1638US11337973B2Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitorsBAYER AG·Filed 2018·Granted May 24, 2022·0 cites·31 claims
- 1738US2021220358A11,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitizationBAYER AG·Filed 2019·Application pending·0 cites
- 1836US10292970B2Heteroaryl-substituted imidazo[1,2-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted May 21, 2019·0 cites·6 claims
- 1936US10174021B2Substituted pyrazolo[1,5-A]pyridines and their useBayer Pharma AG·Filed 2015·Granted Jan 8, 2019·0 cites·7 claims
- 2036US2012237446A1Compounds for binding and imaging amyloid plaques and their useROEHN ULRIKE·Filed 2012·Application pending·0 cites
- 2134US2017240566A1Amino-substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 2234US2017233413A1Substituted annulated pyrimidines and use thereofBayer Pharma AG·Filed 2015·Application pending·0 cites
- 2334US2017057958A1Enantiomers of the n-(2-amino-5-fluoro-2-methylpentyl)-8-[(2,6-difluorobenzyl)oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseasesBayer Pharma AG·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →